about
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertensionProton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansCXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceButyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome.Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals.The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV CoinfectionConversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients.Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria.Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosisDifferential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.Beta blockers and cirrhosis, 2016.Beta adrenergic blockade and decompensated cirrhosis.Acid-base disorders in liver disease.The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study.Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites.Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.Liver Capsule: FXR agonists against liver diseaseResponse-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension.The association of smoking with IGRA and TST results in HIV-1-infected subjects.Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3.Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels.Reversion and conversion of interferon-γ release assay results in HIV-1-infected individuals.The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
P50
Q27310334-81EFF631-150A-4E36-B39B-3C70AE7C46C7Q30418874-492AFABF-79EC-46CD-8A89-18D28E87242EQ33394468-FBEE25F3-1A69-47D1-B882-2290A826245EQ34268818-FF73CF2D-6DFB-494A-A7F3-0AB296BF719EQ34450128-3B338B02-5F46-4E42-B2B3-313DA21FF751Q34796111-03462578-2AE4-4BB7-B538-AD805C269537Q35153222-9BBCB83D-2270-4029-A68E-82618BE1E010Q35528287-6AD4EDB9-41FC-4C68-9F34-109DC574BE65Q35560798-7BE1EBD4-0367-4E86-961A-ED888E00606AQ35760200-C0A8AB17-8AE0-462B-A46B-486A90104D68Q35849638-275BF49C-9CF8-4EB9-BEB5-20E615A5178CQ35886733-02491F33-8A9C-4B26-8A09-2D12755D3CC0Q35985891-C2A7DD98-3BF0-4DAA-9F83-6B1DDB87961FQ37327979-08722B98-21C7-4326-BE41-E0E740F12F93Q37595097-91911D6F-03CC-4D53-9CF4-29C82ED2BEB8Q37666058-AF71E829-2963-45A6-82F9-72775C173FA7Q38770583-89099BAE-0937-48AC-80E6-250BCFA14869Q38975429-F9ABFCA6-6080-4DFA-96E3-0E3A584F5D9FQ39013562-8A7EDA9B-2D68-4F2A-BC15-2C608217BEBDQ39419043-2E1B3DB2-8554-4807-BC75-E1C847B22D9DQ39773776-85E78F98-022E-429A-ACBA-56CBA3ED0330Q40108322-FC25C72B-1751-4EEA-B087-D72533AB0319Q40426656-EA6B122A-D2B8-4DEA-8FD6-301874BAF4E6Q40439414-D24AF786-B8EB-4AA0-92DE-DFA16B65B832Q40727706-77C06012-A628-49BB-800B-904784737AE4Q40761529-3F1AA2E8-2CAD-43B9-A3EE-BCEDBD85B7F6Q40835311-357C255E-70DC-43D0-9E4C-B6FC5E7FF9CDQ40946333-FFEC5B52-E154-4DE7-8D84-027ECE75DD58Q41508212-D28F80FE-1F73-47FC-9EE1-35877B463B78Q41582122-D44BD5F4-09C2-4438-AF80-06EC86D5C710Q41654225-68FC4D09-D1DA-4BBB-864D-3C54289E928BQ41741824-BC79C70C-304A-4581-A27F-475D69426F86Q42210807-84F950D3-FF1B-4A8A-BEC9-E26F3B0699A7Q42211834-6B63927A-0ADC-45B2-B73F-ADD45A8A603EQ42213984-100ACB2C-944C-458C-AE1A-1C70898CCE84Q42248749-058F136C-2CB5-4737-967F-EC6D7B19DDC1Q42249709-A59645B3-C533-44F3-B6FE-18D9C5874195Q42252628-37DBE0AB-3970-4A87-AD1B-6E64ECF4381EQ42255967-CF203571-7052-40A3-9BA9-E28CD61BEF6DQ42263556-C0885C2B-2DE1-4977-906C-71D9528EA579
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas Reiberger
@ast
Thomas Reiberger
@en
Thomas Reiberger
@es
Thomas Reiberger
@nl
Thomas Reiberger
@sl
type
label
Thomas Reiberger
@ast
Thomas Reiberger
@en
Thomas Reiberger
@es
Thomas Reiberger
@nl
Thomas Reiberger
@sl
prefLabel
Thomas Reiberger
@ast
Thomas Reiberger
@en
Thomas Reiberger
@es
Thomas Reiberger
@nl
Thomas Reiberger
@sl
P106
P1153
24315181000
P21
P31
P496
0000-0002-4590-3583